Dolphin 5% is generally used for symptomatic management across common musculoskeletal conditions. The preparation is considered relevant in clinical settings marked by localized pain and inflammation that create noticeable interference with daily stability. The core therapeutic benefit is to offer support that helps ease the overall symptom burden.

Focused Therapeutic Domains

This product is commonly used for managing conditions that present with acute or episodic manifestations, including the discomfort arising from soft-tissue injuries such as sprains, strains, and contusions. It is considered equally relevant for addressing the symptomatic pain and stiffness associated with osteoarthritis and localized inflammatory conditions like tendovaginitis and bursitis. The primary purpose is to address the clusters of pain and swelling that appear suddenly or fluctuate, contributing to improved comfort during periods of heightened symptoms. The medication helps manage symptom intensity across these domains and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact
Relief Focus	Localized Pain and Swelling
Key Symptom Axes	Symptoms that interfere with daily functioning
Core Conditions	Osteoarthritis, Sprains, and Tendon/Bursa inflammation

Regulatory References

1. NIH DailyMed: Diclofenac Sodium Topical Gel Indications

Dolphin 5% (Diclofenac sodium topical gel) eligibility is determined by specific regulatory criteria tied to age, medical history, organ function, and pregnancy status.

Populations for Whom Use is Contraindicated

• Allergy and Sensitivity: Use is strictly contraindicated in patients with a known hypersensitivity to diclofenac or any components of the drug [Source 1.4]. It is also prohibited for those who have experienced allergic reactions (such as asthma, hives, or acute rhinitis) after taking aspirin or other NSAIDs [Source 2.4].
• Surgical Context: The gel is contraindicated for use in the perioperative period of Coronary Artery Bypass Graft (CABG) surgery [Source 1.4].
• Skin Condition: The gel must not be applied to damaged or non-intact skin, including open wounds, infections, or areas with exfoliative dermatitis [Source 1.2].

Age and Specific Conditions

• Pediatric Use: The use of Diclofenac topical gel is generally contraindicated in children and adolescents under 14 years of age, as official data on efficacy and safety in this age group are insufficient [Source 2.4, 2.7].
• Pregnancy: The gel is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation) due to the risk of premature closure of the fetal ductus arteriosus [Source 1.4]. Use is not recommended between 20 and 30 weeks gestation unless clearly needed [Source 2.2].
• Organ Impairment: Use should be avoided in patients with advanced or severe renal disease or severe heart failure unless the benefits outweigh the potential systemic risks [Source 1.4].

Populations for Whom Use is Permitted

• Adults and Adolescents aged 14 years and over are considered eligible for use under standard labeled conditions [Source 2.4]. Elderly patients are eligible, but should be carefully monitored [Source 2.7].

Dolphin 5% is metabolized by two major liver enzymes, Cytochrome P450 (CYP) 2C8 and CYP3A4. Consequently, co-administering Dolphin 5% with other medicinal products that strongly inhibit these enzymes can significantly increase the concentration of Dolphin 5% in the body. This interaction may require a dose adjustment to maintain proper levels.

Interacting Medicinal Products and Substances

Medicines that are strong inhibitors of CYP2C8 or CYP3A4 are known to interact by reducing the metabolism of Dolphin 5%. Regulatory labeling explicitly identifies the following medicines as key examples where a dose reduction is mandatory:

• Gemfibrozil (a strong CYP2C8 inhibitor)
• Itraconazole (a strong CYP3A4 inhibitor)
• Cyclosporine (a potent inhibitor of both CYP2C8 and CYP3A4)

Interacting Product Category	Effect on Dolphin 5% Exposure
Strong CYP2C8 Inhibitors	Significantly increased concentration
Strong CYP3A4 Inhibitors	Significantly increased concentration

Interaction Guidance

When Dolphin 5% is used at the same time as a strong inhibitor of either the CYP2C8 or CYP3A4 enzyme, the recommended dose of Dolphin 5% must be reduced. This measure is required to prevent excessive systemic exposure to the drug, which results from the reduced breakdown and elimination of Dolphin 5% from the body.

Modulation of the Inflammatory Cascade via Enzyme Blockade

This domain covers the primary action where the drug non-competitively inhibits the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which is responsible for synthesizing pro-inflammatory mediators. This enzymatic blockade suppresses the production of key messengers like Prostaglandin E2 (PGE2 ), which are responsible for triggering local vasodilation and increasing vascular permeability. This critical step modifies the early molecular signals that drive inflammation, resulting in diminished tissue fluid accumulation (edema) and reduced nociceptor sensitization.

---

️ Interaction with Peripheral Nerve Signaling

The drug also exerts a supplementary, direct mechanism by interacting with voltage-gated sodium ion channels on the membranes of peripheral nociceptive neurons at high local concentrations. This interaction causes membrane stabilization, which decreases the electrical excitability of the nerve endings. The electrical transmission interaction supplements the mechanism, contributing to a decrease in action potential generation and signal propagation from the local nerve endings.

How to Use Dolphin 5%: Official Administration Guidelines

The usage of Diclofenac Topical Gel is based on a standardized administration protocol to ensure precise and localized delivery of the active ingredient. The sole administration route is topical (cutaneous application) directly onto the skin.

---

Administration Scope and Dosing

Standardized protocols include specific dosing rules based on the size of the joint being treated. The gel must be applied four times daily (Q.I.D.), and the application amount must be measured using the dosing card provided with the product.

Joint Size	Dose per Application	Maximum Daily Dose (per joint)
Upper Extremities (e.g., hand, wrist)	2 grams (g)	8 g
Lower Extremities (e.g., knee, ankle)	4 grams (g)	16 g

The maximum total daily dose across all treatment areas must not exceed 32 g. The medication should be gently massaged completely into the affected skin area.

---

Procedural and Course Constraints

Adherence to the time-bound use schedule is critical. For acute conditions, the duration of use may be limited, and treatment should be reassessed by a healthcare professional if no improvement is seen within seven days.

Following application, specific conditions must be met: hands must be washed immediately, unless they are the site of treatment, and the area must not be covered with an occlusive (airtight) dressing or subjected to external heat. Patients are directed to avoid showering or bathing for at least one hour after the gel is applied. The usual adult dosage applies to older adults, but use is generally not recommended for children and adolescents under 14 years.

Evidence for Acute Soft-Tissue Injuries

Research exploring the use of topical diclofenac gel for sudden, localized injuries like sprains, strains, and contusions relies primarily on short-term, randomized controlled trials (RCTs) focusing on adult populations. These studies measured how patients reported outcomes related to physical discomfort over short periods, typically seven days or less. Findings describe patterns observed in the studies when comparing the drug-containing gel to a non-active vehicle. However, evidence for the specific 5% concentration often relies on the generalization of findings from lower-concentration topical formulations.

---

Evidence for Chronic Localized Osteoarthritis Pain

The research structure for the pain associated with localized osteoarthritis (OA) is based on intermediate-term RCTs that focus on older adults with symptomatic OA of the knee or hand. These studies examined functional outcomes (e.g., using WOMAC indices) and tracked changes in physical discomfort over a study duration, which typically lasted 6 to 12 weeks. Findings indicate that measured changes were observed in some studies that evaluated the drug-containing gel versus the non-active vehicle gel.

---

Long-Term Evidence and Research Gaps

The majority of key clinical trials monitored outcomes over short- or intermediate-term intervals. Consequently, the follow-up durations were limited, and long-term effects are not fully established for sustained use beyond 12 weeks. This means that while studies help show what has been observed so far, the durability of changes and outcomes remains an area where certainty is low. Further research is needed because the data for the specific 5% concentration often relies on findings from trials that evaluated different application vehicles.

---

Research in Specific Populations

Studies primarily monitored superficial joints such as the knee and hand. Data for certain groups, including pediatric populations, patients with certain comorbidities, or those with OA in deeper or more complex joints (like the hip or shoulder), remain insufficient. The results apply only to the populations and specific joint locations that were formally examined.

Key Studies & References

1. Diclofenac Sodium Topical Gel Indications (U.S. National Library of Medicine DailyMed)

Common questions about Dolphin 5% (FAQ)

---

Q: Can older adults use Dolphin 5%?

A: Regulatory documents describe older adults as eligible for use, but advise caution. Monitoring is recommended because this group may have a potentially increased risk for serious adverse reactions affecting the gastrointestinal, cardiovascular, and kidney systems associated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: What is the most common side effect reported for Dolphin 5%?

A: Studies and official information indicate that the most commonly reported reactions occur at the application site. These include local skin issues such as dermatitis, dry skin, rash, itching, and peeling where the gel is applied to the skin.

Q: Can Dolphin 5% cause changes in mood or sleep?

A: Official information lists dizziness and headache as possible side effects. While explicit changes in mood or sleep disturbances are not commonly cited as primary reactions, patients are generally informed to use caution until they are aware of how the medication affects their individual response.

Q: Can Dolphin 5% be used during pregnancy?

A: Use of this medicine is generally limited or advised against during pregnancy. Regulatory documents state it is contraindicated (should not be used) from the start of the third trimester (30 weeks gestation onward) and should be limited between 20 and 30 weeks gestation due to potential risk to the fetus.

Q: Can people with high blood pressure use Dolphin 5%?

A: Regulatory documents indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including topical products, can potentially lead to new onset of high blood pressure (hypertension) or worsen existing hypertension. Official labeling states that monitoring of blood pressure is recommended when starting treatment and throughout the course of therapy.

Q: Does official labeling mention any potential long-term side effects?

A: Official labeling emphasizes that the potential for serious systemic risks, such as kidney injury and increased cardiovascular events, may be greater with longer durations of use. Regulatory guidance advises using the lowest effective dosage for the shortest duration that is consistent with treatment goals.

Q: Can I use Dolphin 5% with common pain relievers like ibuprofen?

A: Official documents advise against the concomitant use with oral NSAIDs (such as ibuprofen or aspirin). This combination is not recommended because it may increase the risk of severe adverse events without providing proven additional benefit.

Q: How long does the effect of Dolphin 5% last?

A: The official product administration schedule directs the product to be applied four times a day (Q.I.D.). This frequency is specified in the administration instructions to maintain the drug's intended therapeutic effect.

Q: Is Dolphin 5% safe to use for a long time?

A: The labeling advises using the lowest effective dosage for the shortest duration necessary to achieve treatment goals. This guidance is based on the potential for increased risk of serious cardiovascular and gastrointestinal events associated with longer duration of NSAID use.

Q: Can I use Dolphin 5% if I have a history of liver issues?

A: Official product information notes that elevated liver tests can occur during use, and monitoring of liver function is generally advised, especially in individuals with existing liver dysfunction.

Q: Does alcohol consumption affect Dolphin 5%?

A: Although the systemic absorption is low, official guidance for NSAIDs notes that consuming three or more alcoholic drinks per day while using the product may increase the risk of serious gastrointestinal bleeding. A healthcare provider can offer guidance regarding alcohol consumption while using this product.

Q: Is Dolphin 5% a prescription-only medicine?

A: The product’s specific regulatory status (whether it is Prescription-Only or Over-the-Counter) is explicitly specified on the drug's official label for its concentration and indication in each region.

Q: What should I do if I miss using a dose of Dolphin 5%?

A: Official instructions typically state that if a dose is missed, administration should continue with the next regularly scheduled dose at the usual time, and a double dose should not be used to make up for the missed application.

Q: Can I use other topical products while using Dolphin 5%?

A: The official label advises against covering the treated area with an occlusive (airtight) dressing or applying external heat. While the use of other non-occlusive topical products is not generally restricted, specific guidance may be necessary depending on the product.

Q: Is it possible for Dolphin 5% to cause weight changes?

A: Regulatory documents indicate that NSAIDs can cause fluid retention, also known as edema. Rapid or unusual weight gain is listed as an adverse event associated with NSAIDs and can be a sign of fluid retention.

Q: Does Dolphin 5% affect kidney function according to official data?

A: Official data confirms that NSAIDs can result in kidney injury, particularly in individuals with existing impaired kidney function. The label advises monitoring kidney function during the course of treatment.

Q: Are there warnings about driving or operating machinery while using Dolphin 5%?

A: Because the product can cause side effects such as dizziness, individuals are generally informed to use caution when driving or operating machinery until they are aware of their response to the medication.

Q: What is the difference between the active and inactive ingredients in Dolphin 5%?

A: The official label specifies Diclofenac sodium as the active ingredient, which is responsible for the medicinal effect. The label also provides a complete, itemized list of all inactive ingredients (excipients) used to form the gel base.

Q: How is Dolphin 5% classified by regulatory bodies?

A: The product is classified pharmacologically as a Non-Steroidal Anti-Inflammatory Drug (NSAID). In addition, regulatory bodies assign it an official marketing status, such as a Human Prescription Drug or an Over-the-Counter medicine.

Q: Is Dolphin 5% described as having potential for drug abuse?

A: Regulatory information indicates that the product is not listed on the DEA Schedule (Controlled Substances Act) in the United States and is not formally described as having potential for drug abuse.

How to Store and Dispose of Dolphin 5%?

The storage and disposal of Dolphin 5% (Diclofenac sodium topical gel) must adhere strictly to official regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

The gel must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The container must remain tightly closed and stored in its original container at all times. It is a mandatory instruction to not freeze the product, as this can compromise the gel's physical integrity. For safety, the medicine must be stored out of the reach and sight of children.

Disposal Requirements

Unused or expired Dolphin 5% should be disposed of by utilizing an authorized drug take-back program. If a take-back program is unavailable, the gel must be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. The product must not be flushed down a toilet or drain.